Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases

BACKGROUND AND AIM: Ustekinumab is approved in Europe for the treatment of moderate to severe Crohn's disease (CD). Italian real‐life data are scarce, so the aim of this study was to assess the effectiveness and safety of ustekinumab in an Italian cohort of CD patients. METHODS: Data of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Viola, Anna, Muscianisi, Marco, Macaluso, Fabio S, Ventimiglia, Marco, Cappello, Maria, Privitera, Antonino C, Magnano, Antonio, Pluchino, Dario, Magrì, Giovanni, Ferracane, Concetta, Mocciaro, Filippo, Garufi, Serena, Giuffrida, Enrica, Costantino, Giuseppe, Fiocco, Gabriele, Grova, Mauro, Guida, Laura, Alibrandi, Angela, Orlando, Ambrogio, Fries, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936616/
https://www.ncbi.nlm.nih.gov/pubmed/33732883
http://dx.doi.org/10.1002/jgh3.12502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936616/
https://www.ncbi.nlm.nih.gov/pubmed/33732883
http://dx.doi.org/10.1002/jgh3.12502

Ejemplares similares